7th Translational Research Conference: Myelodysplastic Syndromes
April 23-25, 2020 – Mandelieu-La Napoule, France
Chairs: Pierre Fenaux, Uwe Platzbecker, Mikkael Sekeres
The conference will be held in the Mandelieu Congress Centre in Mandelieu-La Napoule, France.
Until recently, information on the biology of MDS and options available for its treatment were limited. A lot of data has accumulated in recent years on the pathophysiology of MDS, particularly on the role of somatic mutations (including in very early disease phase), haploinsufficiency for certain genes, and the impact of abnormalities of the microenvironment. Prognostic factors of the disease have also been refined, with the revised IPSS, and new factors like somatic mutations. Treatment approaches are improving, although not at the same speed, and only allogeneic stem cell transplantation remains potentially curative.
The 7th ESH Conference on MDS is designed to provide time and multiple opportunities for critical discussion and informal scientific interaction with internationally recognized experts in the field.
- Learn how to optimally diagnose MDS, mainly by morphological analysis and cytogenetics, but also through the use of new tools, mainly molecular analysis.
- Improve ability to analyze prognostic factors, including new ones (revised IPSS, molecular analysis).
- Review current treatment of MDS, in both the high risk and low risk settings, ranging from single follow up to allogeneic stem cell transplantation.
- Acquire improved knowledge of emerging treatments, based on targeted therapies and well conducted clinical trials. Diagnostic, prognostic and therapeutic issues will be presented by the faculty and ample time will be devoted to discussion with delegates.